Validation of Circulating Biomarkers Using the Immunological Multiparameter Chip Technology (IMPACT) on Plasma Specimens Collected on CALGB 80303
OBJECTIVES:
- To determine whether the observed predictive value of plasma VEGF-A and VEGF-R2 for
overall survival (OS) in study BO17706 can be replicated in study CALGB-80303 using the
same Immunological Multiparameter Chip Technology (IMPACT) assay.
- To determine whether the observed predictive value of plasma VEGF-A and VEGF-R2 for
progression-free survival (PFS), and other circulating biomarkers in study BO17706, can
be replicated in study CALGB-80303 using the same IMPACT assay.
- To explore the relationship between efficacy and other biomarkers measured in the
plasma samples.
OUTLINE: The samples required for this study are stored in the CALGB Pathology Coordinating
Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No
additional samples are required from patients.
The following markers are analyzed in EDTA plasma samples using the Immunological
MultiParameter Chip Technology (IMPACT) a Roche proprietary multiplex enzyme-linked
immunosorbent assay (ELISA) platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3,
IL-8, bFGF, PDGF-C, ICAM-1, and PlGF.
Observational
N/A
Median OS/PFS (95% CI) estimated from Kaplan-Meier curves for patients with low and patients with high biomarker levels
No
Herbert Pang, PhD
Principal Investigator
CALGB Statistical Office at Duke University Medical Center
United States: Institutional Review Board
A151201
NCT01664169
Name | Location |
---|